Literature DB >> 22337890

Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.

Guang Chen1, Si-Meng Chen, Xiang Wang, Xiao-Fei Ding, Jian Ding, Ling-Hua Meng.   

Abstract

CXCL12/CXCR4 plays an important role in metastasis of gastric carcinoma. Rapamycin has been reported to inhibit migration of gastric cancer cells. However, the role of mTOR pathway in CXCL12/CXCR4-mediated cell migration and the potential of drugs targeting PI3K/mTOR pathway remains unelucidated. We found that CXCL12 activated PI3K/Akt/mTOR pathway in MKN-45 cells. Stimulating CHO-K1 cells expressing pEGFP-C1-Grp1-PH fusion protein with CXCL12 resulted in generation of phosphatidylinositol (3,4,5)-triphosphate, which provided direct evidence of activating PI3K by CXCL12. Down-regulation of p110β by siRNA but not p110α blocked phosphorylation of Akt and S6K1 induced by CXCL12. Consistently, p110β-specific inhibitor blocked the CXCL12-activated PI3K/Akt/mTOR pathway. Moreover, CXCR4 immunoprecipitated by anti-p110β antibody increased after CXCL12 stimulation and G(i) protein inhibitor pertussis toxin abrogated CXCL12-induced activation of PI3K. Further studies demonstrated that inhibitors targeting the PI3K/mTOR pathway significantly blocked the chemotactic responses of MKN-45 cells triggered by CXCL12, which might be attributed primarily to inhibition of mTORC1 and related to prevention of F-actin reorganization as well as down-regulation of active RhoA, Rac1, and Cdc42. Furthermore, rapamycin inhibited the secretion of CXCL12 and the expression of CXCR4, which might form a positive feedback loop to further abolish upstream signaling leading to cell migration. Finally, we found cells expressing high levels of cxcl12 were sensitive to rapamycin in its activity inhibiting migration as well as proliferation. In summary, we found that the mTOR pathway played an important role in CXCL12/CXCR4-mediated cell migration and proposed that drugs targeting the mTOR pathway may be used for the therapy of metastatic gastric cancer expressing high levels of cxcl12.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337890      PMCID: PMC3320958          DOI: 10.1074/jbc.M111.302299

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Cell migration: integrating signals from front to back.

Authors:  Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

2.  CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Authors:  Sreenivasa R Chinni; Sivasakthy Sivalogan; Zhong Dong; J Carlos Trindade Filho; Xiyun Deng; R Daniel Bonfil; Michael L Cher
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

Review 3.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

Review 4.  mTOR and cancer therapy.

Authors:  J B Easton; P J Houghton
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

5.  Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.

Authors:  Roderick J Phillips; Javier Mestas; Mehrnaz Gharaee-Kermani; Marie D Burdick; Antonio Sica; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Biol Chem       Date:  2005-03-31       Impact factor: 5.157

6.  Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt.

Authors:  Simone Barbero; Rudy Bonavia; Adriana Bajetto; Carola Porcile; Paolo Pirani; Jean Louis Ravetti; Gian Luigi Zona; Renato Spaziante; Tullio Florio; Gennaro Schettini
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

7.  Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.

Authors:  L Liu; F Li; J A Cardelli; K A Martin; J Blenis; S Huang
Journal:  Oncogene       Date:  2006-05-22       Impact factor: 9.867

8.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

9.  Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.

Authors:  Kawin Leelawat; Surang Leelawat; Siriluck Narong; Suradej Hongeng
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 10.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

View more
  44 in total

Review 1.  Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis.

Authors:  Sasha A Doodnauth; Sergio Grinstein; Michelle E Maxson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

2.  mTORC2 mediates CXCL12-induced angiogenesis.

Authors:  Mary E Ziegler; Michaela M S Hatch; Nan Wu; Steven A Muawad; Christopher C W Hughes
Journal:  Angiogenesis       Date:  2016-04-22       Impact factor: 9.596

Review 3.  Nanoparticle Interactions with the Tumor Microenvironment.

Authors:  Yanyan Huai; Md Nazir Hossen; Stefan Wilhelm; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  Bioconjug Chem       Date:  2019-09-05       Impact factor: 4.774

4.  Genetic variations associated with telomere length confer risk of gastric cardia adenocarcinoma.

Authors:  Nasha Zhang; Yan Zheng; Jie Liu; Tiansui Lei; Yeyang Xu; Ming Yang
Journal:  Gastric Cancer       Date:  2019-03-21       Impact factor: 7.370

5.  CXCL12-induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages.

Authors:  Regina Pacitto; Isabella Gaeta; Joel A Swanson; Sei Yoshida
Journal:  J Leukoc Biol       Date:  2016-10-17       Impact factor: 4.962

6.  A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.

Authors:  Z Xiang; Z-J Zhou; G-K Xia; X-H Zhang; Z-W Wei; J-T Zhu; J Yu; W Chen; Y He; R E Schwarz; R A Brekken; N Awasthi; C-H Zhang
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

7.  Phenotypic Knockout of CXCR4 Expression by a Novel Intrakine Mutant hSDF-1α/54/KDEL Inhibits Breast Cancer Metastasis.

Authors:  Hong-Yuan Chen; Eric S Clayman; Wei-Feng Ma
Journal:  J Interferon Cytokine Res       Date:  2015-05-15       Impact factor: 2.607

Review 8.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 9.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

10.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.